Common Contracts
5 similar Credit Agreement contracts by Osmotica Pharmaceuticals PLC, Osmotica Pharmaceuticals LTD
CONFORMED COPYCredit Agreement • March 30th, 2021 • Osmotica Pharmaceuticals PLC • Pharmaceutical preparations • Delaware
CREDIT AGREEMENT, dated as of February 3, 2016 (this “Agreement”), by and among OSMOTICA PHARMACEUTICAL CORP., a Delaware corporation (“OPC”), ORBIT BLOCKER I LLC, a Delaware limited liability company (“OBI”), ORBIT BLOCKER II LLC, a Delaware limited liability company (“OBII”), VALKYRIE GROUP HOLDINGS, INC., a Delaware corporation (“Valkyrie” and together with OPC, OBI and OBII, the “Borrowers” and sometimes individually, a “Borrower”), OSMOTICA HOLDINGS US LLC, a Delaware limited liability company (“Holdings”), the other Loan Parties (as defined in Article 1), the Lenders (as defined in Article 1) and CIT BANK, N.A. (“CIT”), as administrative agent and collateral agent for the Lenders (in its capacity as administrative agent and collateral agent, the “Administrative Agent”).
THIRD AMENDMENT TO CREDIT AGREEMENTCredit Agreement • September 14th, 2018 • Osmotica Pharmaceuticals PLC • Pharmaceutical preparations • New York
THIS THIRD AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is entered into as of December 21, 2017 by and among, OSMOTICA PHARMACEUTICAL CORP., a Delaware corporation (“OPC”), ORBIT BLOCKER I LLC, a Delaware limited liability company (“OBI”), ORBIT BLOCKER II LLC, a Delaware limited liability company (“OBII”), VALKYRIE GROUP HOLDINGS, INC., a Delaware corporation (“Valkyrie” and together with OPC, OBI and OBII, the “Borrowers”), OSMOTICA HOLDINGS US LLC, a Delaware limited liability company (“Holdings”) in its own capacity and as Borrower Representative, the other Loan Parties party hereto, CIT BANK, N.A. (“CIT”), as Administrative Agent and Swingline Lender, each of the Lenders party to the Existing Credit Agreement referred to below (including those party hereto in their capacity as Departing Lenders (as defined below)) (each, an “Existing Lender”), each other financial institution listed as a Lender on the signature pages hereof that is not an Existing Lender (each, a “New Lender”)
FIRST AMENDMENT TO CREDIT AGREEMENTCredit Agreement • September 14th, 2018 • Osmotica Pharmaceuticals PLC • Pharmaceutical preparations • New York
CREDIT AGREEMENT, dated as of February 3, 2016 (this “Agreement”), by and among OSMOTICA PHARMACEUTICAL CORP., a Delaware corporation (“OPC”), ORBIT BLOCKER I LLC, a Delaware limited liability company (“OBI”), ORBIT BLOCKER II LLC, a Delaware limited liability company (“OBII”), VALKYRIE GROUP HOLDINGS, INC., a Delaware corporation (“Valkyrie” and together with OPC, OBI and OBII, the “Borrowers” and sometimes individually, a “Borrower”), OSMOTICA HOLDINGS US LLC, a Delaware limited liability company (“Holdings”), the other Loan Parties (as defined in Article 1), the Lenders (as defined in Article 1) and CIT BANK, N.A. (“CIT”), as administrative agent and collateral agent for the Lenders (in its capacity as administrative agent and collateral agent, the “Administrative Agent”).
THIRD AMENDMENT TO CREDIT AGREEMENTCredit Agreement • May 9th, 2018 • Osmotica Pharmaceuticals LTD • Pharmaceutical preparations • New York
THIS THIRD AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is entered into as of December 21, 2017 by and among, OSMOTICA PHARMACEUTICAL CORP., a Delaware corporation (“OPC”), ORBIT BLOCKER I LLC, a Delaware limited liability company (“OBI”), ORBIT BLOCKER II LLC, a Delaware limited liability company (“OBII”), VALKYRIE GROUP HOLDINGS, INC., a Delaware corporation (“Valkyrie” and together with OPC, OBI and OBII, the “Borrowers”), OSMOTICA HOLDINGS US LLC, a Delaware limited liability company (“Holdings”) in its own capacity and as Borrower Representative, the other Loan Parties party hereto, CIT BANK, N.A. (“CIT”), as Administrative Agent and Swingline Lender, each of the Lenders party to the Existing Credit Agreement referred to below (including those party hereto in their capacity as Departing Lenders (as defined below)) (each, an “Existing Lender”), each other financial institution listed as a Lender on the signature pages hereof that is not an Existing Lender (each, a “New Lender”)
FIRST AMENDMENT TO CREDIT AGREEMENTCredit Agreement • May 9th, 2018 • Osmotica Pharmaceuticals LTD • Pharmaceutical preparations • New York
CREDIT AGREEMENT, dated as of February 3, 2016 (this “Agreement”), by and among OSMOTICA PHARMACEUTICAL CORP., a Delaware corporation (“OPC”), ORBIT BLOCKER I LLC, a Delaware limited liability company (“OBI”), ORBIT BLOCKER II LLC, a Delaware limited liability company (“OBII”), VALKYRIE GROUP HOLDINGS, INC., a Delaware corporation (“Valkyrie” and together with OPC, OBI and OBII, the “Borrowers” and sometimes individually, a “Borrower”), OSMOTICA HOLDINGS US LLC, a Delaware limited liability company (“Holdings”), the other Loan Parties (as defined in Article 1), the Lenders (as defined in Article 1) and CIT BANK, N.A. (“CIT”), as administrative agent and collateral agent for the Lenders (in its capacity as administrative agent and collateral agent, the “Administrative Agent”).
